Total Payments
$432,390
2024 Payments
$164,390
Companies
26
Transactions
740
Medicare Patients
1,787
Medicare Billing
$306,328
Payment Breakdown by Category
Other$303,124 (70.1%)
Consulting$59,938 (13.9%)
Travel$31,635 (7.3%)
Research$22,090 (5.1%)
Food & Beverage$15,177 (3.5%)
Education$307.80 (0.1%)
Gifts$118.80 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $288,123 | 215 | 66.6% |
| Consulting Fee | $59,938 | 29 | 13.9% |
| Travel and Lodging | $31,635 | 105 | 7.3% |
| Unspecified | $22,090 | 2 | 5.1% |
| Food and Beverage | $15,177 | 362 | 3.5% |
| Honoraria | $10,861 | 8 | 2.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $4,140 | 6 | 1.0% |
| Education | $307.80 | 11 | 0.1% |
| Gift | $118.80 | 2 | 0.0% |
Payments by Type
General
$410,300
738 transactions
Research
$22,090
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $206,749 | 310 | $0 (2024) |
| Novo Nordisk Inc | $56,194 | 96 | $0 (2024) |
| Eli Lilly and Company | $53,089 | 50 | $0 (2024) |
| Abbott Laboratories | $26,998 | 49 | $0 (2024) |
| Xeris Pharmaceuticals, Inc. | $24,204 | 52 | $0 (2024) |
| Ascensia Diabetes Care Us Inc. | $21,827 | 37 | $0 (2024) |
| Senseonics, Incorporated | $16,347 | 19 | $0 (2024) |
| Mannkind Corporation | $15,526 | 36 | $0 (2024) |
| Insulet Corporation | $4,218 | 11 | $0 (2024) |
| Roche Diabetes Care, Inc. | $3,650 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $164,390 | 236 | Lilly USA, LLC ($73,600) |
| 2023 | $114,721 | 208 | Lilly USA, LLC ($59,565) |
| 2022 | $100,951 | 178 | Lilly USA, LLC ($50,557) |
| 2021 | $19,946 | 36 | Lilly USA, LLC ($7,807) |
| 2020 | $11,418 | 33 | Lilly USA, LLC ($11,000) |
| 2019 | $14,492 | 25 | Senseonics, Incorporated ($7,169) |
| 2018 | $5,865 | 15 | Ascensia Diabetes Care US Inc. ($2,918) |
| 2017 | $606.01 | 9 | Novo Nordisk Inc ($169.25) |
All Payment Transactions
740 individual payment records from CMS Open Payments — Page 1 of 30
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $18.81 | General |
| Category: Endocrinology | ||||||
| 12/19/2024 | Insulet Corporation | Omnipod (Device) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $400.00 | General |
| Category: Insulin Pump | ||||||
| 12/19/2024 | Ascensia Diabetes Care Us Inc. | EVERSENSE 365 SENSOR KIT (RETAIL) (Device) | Food and Beverage | In-kind items and services | $6.17 | General |
| Category: Diabetes | ||||||
| 12/17/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $19,050.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY | ||||||
| 12/14/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $115.34 | General |
| Category: Endocrinology | ||||||
| 12/13/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,781.25 | General |
| Category: Diabetes Care | ||||||
| 12/13/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $122.07 | General |
| Category: Diabetes Care | ||||||
| 12/13/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $111.76 | General |
| Category: Endocrinology | ||||||
| 12/13/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $72.81 | General |
| Category: Endocrinology | ||||||
| 12/13/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Travel and Lodging | In-kind items and services | $2.79 | General |
| Category: Diabetes Care | ||||||
| 12/12/2024 | Ascensia Diabetes Care Us Inc. | EVERSENSE 365 SENSOR KIT (RETAIL) (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,087.50 | General |
| Category: Diabetes | ||||||
| 12/12/2024 | Ascensia Diabetes Care Us Inc. | — | Consulting Fee | Cash or cash equivalent | $1,275.00 | General |
| 12/11/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $4,400.00 | General |
| 12/11/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,925.00 | General |
| 12/11/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,900.00 | General |
| Category: Diabetes Care | ||||||
| 12/07/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $32.43 | General |
| Category: Endocrinology | ||||||
| 12/07/2024 | Ascensia Diabetes Care Us Inc. | EVERSENSE 365 SENSOR KIT (RETAIL) (Device) | Food and Beverage | In-kind items and services | $24.60 | General |
| Category: Diabetes | ||||||
| 12/05/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $16.97 | General |
| Category: Diabetes Care | ||||||
| 12/05/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $4.73 | General |
| Category: Diabetes Care | ||||||
| 11/27/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $124.94 | General |
| Category: Endocrinology | ||||||
| 11/25/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $89.39 | General |
| Category: Endocrinology | ||||||
| 11/21/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $21.01 | General |
| Category: Diabetes | ||||||
| 11/18/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $99.27 | General |
| Category: Endocrinology | ||||||
| 11/15/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Travel and Lodging | In-kind items and services | $332.91 | General |
| Category: Diabetes Care | ||||||
| 11/15/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $142.47 | General |
| Category: Diabetes Care | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY | Eli Lilly and Company | $22,090 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 644 | 1,173 | $287,775 | $109,411 |
| 2022 | 4 | 363 | 626 | $127,500 | $56,269 |
| 2021 | 7 | 454 | 898 | $169,505 | $83,593 |
| 2020 | 7 | 326 | 645 | $111,330 | $57,055 |
Total Patients
1,787
Total Services
3,342
Medicare Billing
$306,328
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 304 | 676 | $168,675 | $70,886 | 42.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 135 | 135 | $47,250 | $18,317 | 38.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 52 | 52 | $41,600 | $8,949 | 21.5% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 129 | 282 | $21,150 | $7,901 | 37.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 24 | 28 | $9,100 | $3,358 | 36.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 201 | 384 | $86,400 | $39,895 | 46.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 71 | 71 | $17,750 | $8,839 | 49.8% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 74 | 154 | $11,550 | $4,413 | 38.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 17 | 17 | $11,800 | $3,122 | 26.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 197 | 489 | $103,965 | $52,796 | 50.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 74 | 74 | $18,500 | $10,730 | 58.0% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 98 | 243 | $18,225 | $7,269 | 39.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 34 | 39 | $11,915 | $6,053 | 50.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 22 | 22 | $11,000 | $4,125 | 37.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 18 | 20 | $3,700 | $1,542 | 41.7% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 11 | 11 | $2,200 | $1,079 | 49.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 129 | 292 | $48,315 | $27,185 | 56.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 59 | 118 | $29,465 | $13,785 | 46.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 29 | 29 | $9,500 | $5,127 | 54.0% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 34 | 34 | $8,500 | $4,564 | 53.7% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2020 | 51 | 144 | $10,800 | $4,352 | 40.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 13 | 17 | $2,550 | $1,086 | 42.6% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 11 | 11 | $2,200 | $957.08 | 43.5% |
About Dr. David Ahn, MD
Dr. David Ahn, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Newport Beach, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/29/2010. The National Provider Identifier (NPI) number assigned to this provider is 1184949570.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Ahn, MD has received a total of $432,390 in payments from pharmaceutical and medical device companies, with $164,390 received in 2024. These payments were reported across 740 transactions from 26 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($288,123).
As a Medicare-enrolled provider, Ahn has provided services to 1,787 Medicare beneficiaries, totaling 3,342 services with total Medicare billing of $306,328. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Newport Beach, CA
- Active Since 03/29/2010
- Last Updated 09/25/2018
- Taxonomy Code 207RE0101X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1184949570
Products in Payments
- MOUNJARO (Drug) $133,084
- Rybelsus (Drug) $37,742
- FREESTYLE LIBRE 3 (Device) $26,761
- Eversense (Device) $16,347
- Ozempic (Drug) $15,933
- AFREZZA (Drug) $15,526
- GVOKE HYPOPEN (Drug) $14,438
- LYUMJEV (Drug) $14,239
- GVOKE PFS (Drug) $9,766
- EVERSENSE E3 SENSOR KIT - RETAIL (Device) $8,695
- Omnipod (Device) $4,218
- Accu-Chek Inform II Instrument with RF card (Device) $3,650
- EVERSENSE 365 SENSOR KIT (RETAIL) (Device) $3,163
- CONTOUR NEXT ONE Meter (Device) $2,918
- Dexcom G6 Transmitter (Medical Supply) $1,212
- ZEGALOGUE (Drug) $412.43
- MINIMED 780G (Device) $279.92
- Victoza (Drug) $213.57
- JARDIANCE (Drug) $193.49
- V-GO (Device) $184.32
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Newport Beach
Sandeep Sodhi, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $263,038
Endocrinology, Diabetes & Metabolism $263,038
Sean Nikravan, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $96,945
Endocrinology, Diabetes & Metabolism $96,945
Dr. Sandra Kwak, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $41,403
Endocrinology, Diabetes & Metabolism $41,403
Dr. Amy Teresi, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $23,125
Endocrinology, Diabetes & Metabolism $23,125
Dr. Duc Do, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $17,050
Endocrinology, Diabetes & Metabolism $17,050
Tanzila Razzaki, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $1,239
Endocrinology, Diabetes & Metabolism $1,239